{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T21:22:08Z","timestamp":1784236928112,"version":"3.55.0"},"reference-count":22,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"12","license":[{"start":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:00:00Z","timestamp":1735171200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trans. Vis. Sci. Tech."],"published-print":{"date-parts":[[2024,12,26]]},"DOI":"10.1167\/tvst.13.12.35","type":"journal-article","created":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T12:30:51Z","timestamp":1735216251000},"page":"35","source":"Crossref","is-referenced-by-count":6,"title":["Changes in Aqueous Angiopoietin-1\/2 Concentrations During the Induction Phase of Intravitreal Faricimab Injections for Diabetic Macular Edema"],"prefix":"10.1167","volume":"13","author":[{"given":"Masahiko","family":"Shimura","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Tokyo Medical University Hachioji Medical Center, Hachioji, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Tokyo Medical University Hachioji Medical Center, Hachioji, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Nonaka","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Tokyo Medical University Hachioji Medical Center, Hachioji, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikumi","family":"Kashiwagi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Tokyo Medical University Hachioji Medical Center, Hachioji, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Tokyo Medical University Hachioji Medical Center, Hachioji, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetaka","family":"Noma","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Tokyo Medical University Hachioji Medical Center, Hachioji, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Takagi","sequence":"additional","affiliation":[{"name":"Kawasaki-Tama Eye Clinic, Kawasaki, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","reference":[{"key":"bib1","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.ophtha.2015.03.024","article-title":"Diabetic macular edema: pathophysiology and novel therapeutic targets","volume":"122","author":"Das","year":"2015","journal-title":"Ophthalmology."},{"key":"bib2","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s11892-014-0510-4","article-title":"Anti-VEGF therapy for diabetic macular edema","volume":"14","author":"Stewart","year":"2014","journal-title":"Curr Diab Rep."},{"key":"bib3","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1136\/bjophthalmol-2019-315726","article-title":"Real-world management of treatment-naive diabetic macular oedema: 2-year visual outcome focusing on the starting year of intervention from STREAT-DMO study","volume":"104","author":"Shimura","year":"2020","journal-title":"Br J Ophthalmol."},{"key":"bib4","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1001\/jamaophthalmol.2015.5346","article-title":"Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment","volume":"134","author":"Bressler","year":"2016","journal-title":"JAMA Ophthalmol."},{"key":"bib5","doi-asserted-by":"publisher","first-page":"333","DOI":"10.4239\/wjd.v7.i16.333","article-title":"Treatment of diabetic retinopathy: recent advances and unresolved challenges","volume":"7","author":"Stewart","year":"2016","journal-title":"World J Diabetes."},{"key":"bib6","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.3390\/cells11121950","article-title":"Current and novel therapeutic approaches for treatment of diabetic macular edema","volume":"11","author":"Chauhan","year":"2022","journal-title":"Cells."},{"key":"bib7","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.ophtha.2007.03.057","article-title":"Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema","volume":"114","author":"Diabetic Retinopathy Clinical Research Network","year":"2007","journal-title":"Ophthalmology."},{"key":"bib8","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s11892-016-0816-5","article-title":"Targeting Tie2 for treatment of diabetic retinopathy and diabetic macular edema","volume":"16","author":"Campochiaro","year":"2016","journal-title":"Curr Diab Rep."},{"key":"bib9","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1161\/01.RES.0000102937.50486.1B","article-title":"Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1","volume":"93","author":"Kelly","year":"2003","journal-title":"Circ Res."},{"key":"bib10","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1167\/iovs.10-6386","article-title":"A potential role for angiopoietin 2 in the regulation of the blood-retinal barrier in diabetic retinopathy","volume":"52","author":"Rangasamy","year":"2011","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"bib11","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet."},{"key":"bib12","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.15252\/emmm.201505889","article-title":"Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases","volume":"8","author":"Regula","year":"2016","journal-title":"EMBO Mol Med."},{"key":"bib13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000508953","article-title":"Anti-VEGF therapy reduces inflammation in diabetic macular edema","volume":"64","author":"Imazeki","year":"2021","journal-title":"Ophthalmic Res."},{"key":"bib14","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s10384-024-01078-y","article-title":"Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in diabetic macular edema: 2-year results from the Japan subgroup of the phase 3 YOSEMITE trial","volume":"68","author":"Shimura","year":"2024","journal-title":"Jpn J Ophthalmol."},{"key":"bib15","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s10384-023-00979-8","article-title":"Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial","volume":"67","author":"Shimura","year":"2023","journal-title":"Jpn J Ophthalmol."},{"key":"bib16","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/j.1755-3768.2012.02473.x","article-title":"Ang-2 upregulation correlates with increased levels of MMP-9, VEGF, EPO and TGFbeta1 in diabetic eyes undergoing vitrectomy","volume":"91","author":"Loukovaara","year":"2013","journal-title":"Acta Ophthalmol."},{"key":"bib17","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.3390\/pharmaceutics15051413","article-title":"Faricimab for the treatment of diabetic macular edema and neovascular age-related macular degeneration","volume":"15","author":"Ferro Desideri","year":"2023","journal-title":"Pharmaceutics."},{"key":"bib18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1167\/iovs.65.11.15","article-title":"Aqueous humor cytokine analysis in age-related macular degeneration after switching from aflibercept to faricimab","volume":"65","author":"Todoroki","year":"2024","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"bib19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.bbrc.2015.11.108","article-title":"Expression of angiopoietin-1 in hypoxic pericytes: regulation by hypoxia-inducible factor-2alpha and participation in endothelial cell migration and tube formation","volume":"469","author":"Park","year":"2016","journal-title":"Biochem Biophys Res Commun."},{"key":"bib20","doi-asserted-by":"publisher","first-page":"e0280488","DOI":"10.1371\/journal.pone.0280488","article-title":"Increased angiopoietin-1 and -2 levels in human vitreous are associated with proliferative diabetic retinopathy","volume":"18","author":"Tsai","year":"2023","journal-title":"PLoS One."},{"key":"bib21","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1007\/s00417-021-05154-8","article-title":"Effects of ranibizumab on growth factors and mediators of inflammation in the aqueous humor of patients with diabetic macular edema","volume":"259","author":"Utsumi","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"bib22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00417-022-05745-z","article-title":"Serum Ang-1\/Ang-2 ratio may be a promising biomarker for evaluating severity of diabetic retinopathy","volume":"261","author":"Wang","year":"2023","journal-title":"Graefes Arch Clin Exp Ophthalmol."}],"container-title":["Translational Vision Science & Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2802387","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T12:30:53Z","timestamp":1735216253000},"score":1,"resource":{"primary":{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2802387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,26]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12,2]]}},"URL":"https:\/\/doi.org\/10.1167\/tvst.13.12.35","relation":{},"ISSN":["2164-2591"],"issn-type":[{"value":"2164-2591","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,26]]}}}